Meeting
2020 ASCO Virtual Scientific Program
Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.
Authors
Michael Wang
The University of Texas MD Anderson Cancer Center, Houston, TX
Michael Wang , John M. Rossi , Javier Munoz , Andre Goy , Frederick Lundry Locke , Patrick Michael Reagan , Caron A. Jacobson , Brian T Hill , Houston Holmes , Samantha Mary Jaglowski , Weimin Peng , Lianqing Zheng , Xiang Fang , Allen Xue , Arati V. Rao , Adrian Bot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT02601313
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3023)
DOI
10.1200/JCO.2020.38.15_suppl.3023
Abstract #
3023
Poster Bd #
87
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Immune characterization of urothelial bladder carcinoma integrating transurethral resection of bladder tumor (TURBT) samples and serum: A feasibility study.
First Author: Carmen Alvarez-Dominguez
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2023 ASCO Annual Meeting
MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data.
First Author: Minal A. Barve
Poster
2022 ASCO Annual Meeting
First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.
First Author: Eugene R Ahn